Lumatix Biotech aims to develop a revolutionary affinity chromatography technology to significantly advance antibody manufacturing. The startup is located in the Munich area and currently funded by the Federal Ministry for Economy Affairs and Energy.
Biotherapeutics, such as antibodies, have been successful in treating many life-threatening diseases. However, these therapeutic proteins are expensive and sensitive to harsh purification conditions, driving the need for alternatives in antibody purification. A significant proportion of costs arise from the protein A capture step during manufacturing. Lumatix Biotech is developing an innovatively controlled affinity matrix, allowing cost effective and mild purification of classic antibodies as well as a wide range of antibody formats.